tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kevin Kedra, 5 are a HOLD (35.71%), 2 are a SELL (14.29%), 7 are a BUY (50%).
Analyst Kevin Kedra, carries an average stock price target met ratio of 91.67% that have a potential upside of 51.15% achieved within 554 days. Previously, Kevin Kedra worked at GABELLI.
Kevin Kedra’s has documented 32 price targets and ratings displayed on 6 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on ELAN, Elanco Animal Health at 17-Jun-2021.
Analyst best performing recommendations are on LXRX (LEXICON PHARMACEUTICALS).
The best stock recommendation documented was for LXRX (LEXICON PHARMACEUTICALS) at 3/14/2019. The price target of $6 was fulfilled within 11 days with a profit of $1.33 (18.14%) receiving and performance score of 16.5.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 15-Jan-2021
$3.1
$0.55 (21.57%)
$2.3
5 months 11 days ago
(11-May-2026)
4/13 (30.77%)
$0.79 (34.20%)
85
Buy Since 16-Jul-2024
$6
$3.45 (135.29%)
$6
6 months 29 days ago
(23-Mar-2026)
0/15 (0%)
$4.36 (265.85%)
Hold Since 07-Mar-2023
$0.85
$-1.7 (-66.67%)
$3
1 years 2 months 16 days ago
(06-Aug-2025)
1/2 (50%)
$-0.3 (-26.09%)
58
Buy Since 12-Aug-2022
$10
1 years 7 months 15 days ago
(07-Mar-2025)
0/8 (0%)
$7.99 (397.51%)
Hold Since 11-Mar-2021
$6
$4.48 (294.74%)
$10
5 years 7 months 11 days ago
(11-Mar-2021)
1/3 (33.33%)
$-0.95 (-13.67%)
13
